{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:46:39Z","timestamp":1793292399608,"version":"4.5.0"},"reference-count":35,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T00:00:00Z","timestamp":1542758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Spironolactone, a non-selective mineralocorticoid receptor antagonist, can protect against cardiac fibrosis and left ventricular dysfunction, and improve endothelial dysfunction and proteinuria. However, the safety and effects of spironolactone on patient-centered cardiovascular and renal endpoints remain unclear. Methods: We identified predialysis stage 3\u20134 chronic kidney disease (CKD) patients between 2000 and 2013 from the Longitudinal Health Insurance Database 2005 (LHID 2005). The outcomes of interest were end-stage renal disease (ESRD), major adverse cardiovascular events (MACE), hospitalization for heart failure (HHF), hyperkalemia-associated hospitalization (HKAH), all-cause mortality and cardiovascular mortality. The Fine and Gray sub-distribution hazards approach was adopted to adjust for the competing risk of death. Results: After the propensity score matching, 693 patients with stage 3\u20134 CKD were spironolactone users and 1386 were nonusers. During the follow-up period, spironolactone users had a lower incidence rate for ESRD than spironolactone non-users (39.2 vs. 53.69 per 1000 person-years) and a higher incidence rate for HKAH (54.79 vs. 18.57 per 1000 person-years). The adjusted hazard ratios for ESRD of spironolactone users versus non-users were 0.66 (95% CI, 0.51\u20130.84; p value &lt; 0.001) and 3.17 (95% CI, 2.41\u20134.17; p value &lt; 0.001) for HKAH. A dose-response relationship was found between spironolactone use and risk of ESRD and HKAH. There were no statistical differences in MACE, HHF, all-cause mortality and cardiovascular mortality between spironolactone users and non-users. Conclusion: Spironolactone represented a promising treatment option to retard CKD progression to ESRD amongst stage 3\u20134 CKD patients, but strategic treatments to prevent hyperkalemia should be enforced.<\/jats:p>","DOI":"10.3390\/jcm7110459","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T09:18:25Z","timestamp":1542878305000},"page":"459","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease"],"prefix":"10.3390","volume":"7","author":[{"given":"Chen-Ta","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Changhua Christian Hospital, Changhua 50006, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chew-Teng","family":"Kor","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Changhua Christian Hospital, Changhua 50006, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Peng","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Changhua Christian Hospital, Changhua 50006, Taiwan"},{"name":"School of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan"},{"name":"School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,11,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1681\/ASN.2005101085","article-title":"Chronic kidney disease and mortality risk: A systematic review","volume":"17","author":"Tonelli","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/ndt\/gfl291","article-title":"The impact of traditional and nontraditional risk factors on coronary calcification in pre-dialysis patients","volume":"21","author":"Tomiyama","year":"2006","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1053\/snep.2001.26793","article-title":"Role of angiotensin II in glomerular injury","volume":"21","author":"Ma","year":"2001","journal-title":"Semin. Nephrol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study","volume":"10","author":"McElvie","year":"1999","journal-title":"Circulation"},{"key":"ref_8","first-page":"CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"4","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1177\/1470320315575849","article-title":"Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis","volume":"16","author":"Ng","year":"2015","journal-title":"J. Renin. Angiotensin Aldosterone Syst."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-8587(14)70216-5","article-title":"Mineralocorticoid receptor antagonists: Part of an emerging treatment paradigm for chronic kidney disease","volume":"2","author":"Epstein","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2174\/157488711795177912","article-title":"Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition","volume":"6","author":"Alfie","year":"2011","journal-title":"Rev. Recent Clin. Trials"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/HJH.0b013e32834d9e0f","article-title":"Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression","volume":"30","author":"Cerezo","year":"2012","journal-title":"J. Hypertens."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2009.03.066","article-title":"Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: A randomized controlled trial","volume":"54","author":"Edwards","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.ajkd.2008.02.297","article-title":"Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: An open-label crossover randomized controlled trial","volume":"52","author":"Tylicki","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3892\/etm.2013.1335","article-title":"Effect of spironolactone combined with angiotensin converting enzyme inhibitors and\/or angiotensin II receptor blockers on chronic glomerular disease","volume":"6","author":"Wang","year":"2013","journal-title":"Exp. Ther. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Currie, G., Taylor, A.H., Fujita, T., Ohtsu, H., Lindhardt, M., Rossing, P., Boesby, L., Edwards, N.C., Ferro, C.J., and Townend, J.N. (2016). Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: A systematic review and meta-analysis. BMC Nephrol., 17.","DOI":"10.1186\/s12882-016-0337-0"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejphar.2008.06.019","article-title":"Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats","volume":"589","author":"Taira","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10157-011-0498-x","article-title":"Aldosterone stimulates nuclear factor-kappa b activity and transcription of intercellular adhesion molecule-1 and connective tissue growth factor in rat mesangial cells via serum- and glucocorticoid-inducible protein kinase-1","volume":"16","author":"Terada","year":"2012","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.freeradbiomed.2012.10.549","article-title":"Blood pressure has only minor influence on aldosterone-induced oxidative stress and DNA damage in vivo","volume":"54","author":"Queisser","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone: A mediator of myocardial necrosis and renal arteriopathy","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10157-010-0373-1","article-title":"Aldosterone-induced kidney injury is mediated by NF\u03baB activation","volume":"15","author":"Fukuda","year":"2011","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/ndt\/gfr495","article-title":"Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease","volume":"27","author":"Lian","year":"2012","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1159\/000228080","article-title":"Aldosterone induces apoptosis in rat podocytes: Role of PI3-K\/Akt and p38MAPK signaling pathways","volume":"113","author":"Chen","year":"2009","journal-title":"Nephron Exp. Nephrol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/01.HYP.0000157408.43807.5a","article-title":"Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway","volume":"45","author":"Kobayashi","year":"2005","journal-title":"Hypertension"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"F1020","DOI":"10.1152\/ajprenal.00166.2005","article-title":"Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity","volume":"289","author":"Derive","year":"2005","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/ki.2012.170","article-title":"Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin ii-induced cardiac, renal, and vascular injury","volume":"82","author":"Luther","year":"2012","journal-title":"Kidney Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/01.HYP.0000222003.28517.99","article-title":"Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker","volume":"47","author":"Nagase","year":"2006","journal-title":"Hypertension"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1093\/ndt\/gfp371","article-title":"Increased renoprotection with ACE inhibitor plus aldosterone antagonist as compared to monotherapies\u2014The effect on podocytes","volume":"24","author":"Nemeth","year":"2009","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijcard.2017.03.080","article-title":"Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study","volume":"238","author":"Tseng","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJM200006223422506","article-title":"A comparison of observational studies and randomized, controlled trials","volume":"342","author":"Benson","year":"2000","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/7\/11\/459\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:31:09Z","timestamp":1760196669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/7\/11\/459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,21]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11]]}},"alternative-id":["jcm7110459"],"URL":"https:\/\/doi.org\/10.3390\/jcm7110459","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,21]]}}}